Abstract:Motivation: In solid tumors, anti-inflammatory cytokines such as IL10 and TGFβ support an immunosuppressive tumor microenvironment (TME) and inhibit anti-tumor immunity. Many therapeutic approaches to overcome immunosuppression have used monoclonal antibodies to block cytokine signaling. Instead of silencing TME-associated cytokines, a more powerful strategy may be to leverage them as disease markers and convert them into anti-tumor signals, using a logic-gated cell-based immunotherapy. Here, we engineered macrophages with synthetic cytokine switch receptors (SR) that convert IL10 or TGFβ into pro-inflammatory signals. Macrophages are homeostatic regulators capable of both infiltrating solid tumors and initiating inflammation, and we harnessed this proficiency using SRs that convert prevalent cytokines in the TME into pro-inflammatory responses for TME modulation. We termed this engineered myeloid cell platform "Engineered Microenvironment Converters" (EM-C) and evaluated its ability to overcome cytokine-mediated immunosuppression in solid tumors. Methods: EM-C were produced by transducing primary macrophages or monocytes with a SR that converts IL10 into an interferon-based signal. The response of EM-C to IL10 was monitored in vitro using phenotypic characterization of surface molecules, measurement of secreted factors, and mRNA profiling. The in vivo activity of EM-C was evaluated using a subcutaneous tumor model in immunocompetent mice. Murine EM-C were administered to tumor-bearing mice, and their ability to modulate the TME was monitored via immunophenotyping, secretome analysis, and single cell transcriptomics. To demonstrate modularity of the EM-C platform, additional SR were designed to convert TGFβ into interferon or toll-like receptor signals. Results: EM-C efficiently sequestered IL10 or TGFβ and upregulated pro-inflammatory markers, cytokines, and pathways in a dose-dependent manner in vitro. EM-C administered to tumor-bearing mice remodeled the TME immune compartment by increasing the abundance of CD8 T cells and reducing the presence of immunosuppressive Tregs. EM-C furthermore augmented the cytokine/chemokine profile of the TME in a manner that correlated with anti-tumor response. TME modulation by EM-C improved tumor control, as compared to non-engineered macrophages, and had additive efficacy with checkpoint blockade. Conclusion: We present a versatile immunotherapy platform that harnesses macrophages as "living converters" to locally augment inflammation in solid tumors. EM-C exhibit a modular ability to locally convert IL10 or TGFβ into pro-inflammatory signals without systemic cytokine antagonism. The EM-C platform enables development of target antigen-agnostic myeloid cell immunotherapies for overcoming immunosuppression in diverse solid tumors. Citation Format: Chris Sloas, Silvia Beghi, Yuhao Huangfu, Rehman Qureshi, Benjamin Schott, Michael Ball, Daniel Blumenthal, Thomas Condamine, Michael Klichinsky, Yumi Ohtani. Macrophages expressing synthetic cytokine receptors reverse IL10-mediated immunosuppression within solid tumors and promote adaptive immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5249.

Proinflammatory polarization of engineered heat-inducible macrophages reprogram the tumor immune microenvironment during cancer immunotherapy

Metabolic Reprogramming via targeting ACOD1 promotes polarization and anti-tumor activity of human CAR-iMACs in solid tumors

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor-Associated Macrophages to Potentiate Cancer Immunotherapy

Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities

Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity

Polymeric Nanoparticles Promote Macrophage Reversal from M2 to M1 Phenotypes in the Tumor Microenvironment.

Polarization of macrophages to an anti-cancer phenotype through in situ uncaging of a TLR 7/8 agonist using bioorthogonal nanozymes

Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials

Metabolic Reprogramming Induces Macrophage Polarization in the Tumor Microenvironment

Abstract 5249: Macrophages expressing synthetic cytokine receptors reverse IL10-mediated immunosuppression within solid tumors and promote adaptive immunity

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

Reprogramming Macrophages toward Pro-inflammatory Polarization by Peptide Hydrogel

Wireless Localized Electrical Stimulation Generated by an Ultrasound‐Driven Piezoelectric Discharge Regulates Proinflammatory Macrophage Polarization

In Situ Reprogramming of Tumor-Associated Macrophages Enhances Cancer Immunotherapy

Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy

Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy

Cryo-thermal Therapy Inducing MI Macrophage Polarization Created CXCL10 and IL-6-rich Pro-Inflammatory Environment for CD4+ T Cell-Mediated Anti-Tumor Immunity.

Modulating and Imaging Macrophage Reprogramming for Cancer Immunotherapy